Last reviewed · How we verify
Protein pump inhibitor.
The drug, a protein pump inhibitor developed by Odense University Hospital, is currently marketed but lacks detailed revenue figures and primary indication data. A key strength is the protection of its core composition patent, which expires in 2028, providing a period of exclusivity. The primary risk is the lack of clear competitive positioning and trial results, which may impact market adoption and reimbursement.
At a glance
| Generic name | Protein pump inhibitor. |
|---|---|
| Also known as | Omeprazole |
| Sponsor | Odense University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (PHASE1)
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia (NA)
- Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal (NA)
- Treatment of Gastroesophageal Reflux Disease in Infants (PHASE4)
- Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat (PHASE1)
- Triple Therapy in T1DM (PHASE2, PHASE3)
- Baricitinib in CPPD - the BAPTIST Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Protein pump inhibitor. CI brief — competitive landscape report
- Protein pump inhibitor. updates RSS · CI watch RSS
- Odense University Hospital portfolio CI